Analyzing Actelion (ALIOF) & MediWound (MDWD)

Actelion (OTCMKTS: ALIOF) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Valuation & Earnings

How to Become a New Pot Stock Millionaire

This table compares Actelion and MediWound’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Actelion $2.46 billion 12.17 $707.04 million N/A N/A
MediWound $2.50 million 58.43 -$22.14 million ($0.62) -8.71

Actelion has higher revenue and earnings than MediWound.

Profitability

This table compares Actelion and MediWound’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Actelion N/A N/A N/A
MediWound -887.38% -234.12% -38.22%

Volatility & Risk

Actelion has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, MediWound has a beta of -0.18, meaning that its share price is 118% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Actelion and MediWound, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Actelion 0 0 0 0 N/A
MediWound 0 0 6 0 3.00

MediWound has a consensus price target of $9.83, indicating a potential upside of 82.10%. Given MediWound’s higher probable upside, analysts clearly believe MediWound is more favorable than Actelion.

Institutional & Insider Ownership

32.9% of MediWound shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Actelion beats MediWound on 6 of the 10 factors compared between the two stocks.

Actelion Company Profile

Actelion Ltd. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of low molecular weight drugs. It specializes in the field of pulmonary arterial hypertension (PAH). It also specializes in human biology, especially in specific families of molecular targets, such as G-Protein Coupled Receptors. Its portfolio of PAH treatments covers the spectrum of disease, from World Health Organization (WHO) Functional Class (FC) II through to Functional Class (FC) IV, with oral, inhaled and intravenous medications. It also has treatments for a range of specialist diseases, including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides type cutaneous T-cell lymphoma. Its products include Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Ventavis (iloprost), Veletri (epoprostenol for injection), Zavesca (miglustat) and Valchlor (mechlorethamine) gel.

MediWound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Receive News & Ratings for Actelion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actelion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply